Jennifer Dewing

Dr. Jennifer Dewing


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2019 in Cells
Verified
Journal Article
Open access
PDF file
JDJennifer Dewing
Jennifer Dewing
RCRoxana Octavia Carare
Roxana Octavia Carare
ALAndrew J Lotery
Andrew J Lotery
JRJ. Arjuna Ratnayaka
J. Arjuna Ratnayaka
Tissue inhibitor of metalloproteinase-3 (TIMP-3) is a component of the extracellular environment, where it mediates diverse processes including matrix regulation/turnover, inflammation and angiogenesis. Rare TIMP-3 risk alleles and mutations are directly linked with retinopathies such as age-related macular degeneration (AMD) and Sorsby fundus dystrophy, and potentially, through indirect mechanisms, with Alzheimer’s disease. Insights into TIMP-3 activities may be gleaned from studying Sorsby-linked mutations. However, recent findings do not fully support the prevailing hypothesis that a gain of function through the dimerisation of mutated TIMP-3 is responsible for retinopathy. Findings from Alzheimer’s patients suggest a hitherto poorly studied relationship between TIMP-3 and the Alzheimer’s-linked amyloid-beta (A) proteins that warrant further scrutiny. This may also have implications for understanding AMD as aged/diseased retinae contain high levels of A. Findings from TIMP-3 knockout and mutant knock-in mice have not led to new treatments, particularly as the latter does not satisfactorily recapitulate the Sorsby phenotype. However, recent advances in stem cell and in vitro approaches offer novel insights into understanding TIMP-3 pathology in the retina-brain axis, which has so far not been collectively examined. We propose that TIMP-3 activities could extend beyond its hitherto supposed functions to cause age-related changes and disease in these organs.

30 November 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JDJennifer Dewing
Jennifer Dewing
VSVinay Saunders
Vinay Saunders
IOIta O’kelly
Ita O’kelly
DWDavid I. Wilson
David I. Wilson
While the adult human heart is primarily composed of cardiomyocytes, fibroblasts, endothelial and smooth muscle cells, the cellular composition during early development remains largely unknown. Reliable identification of fetal cardiac cell types using protein markers is critical to understand cardiac development and delineate the cellular composition of the developing human heart. This is the first study to use immunohistochemistry (IHC), flow cytometry and RT-PCR analyses to investigate the expression and specificity of commonly used cardiac cell markers in the early human fetal heart (8–12 post-conception weeks). The expression of previously reported protein markers for the detection of cardiomyocytes (Myosin Heavy Chain (MHC) and cardiac troponin I (cTnI), fibroblasts (DDR2, THY1, Vimentin), endothelial cells (CD31) and smooth muscle cells (α-SMA) were assessed. Two distinct populations of cTnI positive cells were identified through flow cytometry, with MHC positive cardiomyocytes showing high cTnI expression (cTnIHigh) while MHC negative non-myocytes showed lower cTnI expression (cTnILow). cTnI expression in non-myocytes was further confirmed by IHC and RT-PCR analyses, suggesting troponins are not cardiomyocyte-specific and may play distinct roles in non-muscle cells during early development. Vimentin (VIM) was expressed in cultured ventricular fibroblast populations and flow cytometry revealed VIMHighand VIMLowcell populations in the fetal heart. MHC positive cardiomyocytes were VIMLowwhilst CD31 positive endothelial cells were VIMHigh. Using markers investigated within this study, we characterised fetal human cardiac populations and estimate that 75–80% of fetal cardiac cells are cardiomyocytes and are MHC+/cTnIHigh/VIMLow, whilst non-myocytes comprise 20–25% of total cells and are MHC-/cTnILow/VIMHigh, with CD31+endothelial cells comprising ~9% of this population. These findings show distinct differences from those reported for adult heart.

15 July 2020 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
HHHeidi Hongisto
Heidi Hongisto
JDJennifer Dewing
Jennifer Dewing
DCDavid R. G. Christensen
David R. G. Christensen
JSJennifer Scott
Jennifer Scott
ACAngela J. Cree
Angela J. Cree
ALAndrew J Lotery
Andrew J Lotery

18 April 2025 in Cells
Verified
Journal Article
Open access
PDF file
JDJennifer Dewing
Jennifer Dewing
AKAbby Keable
Abby Keable
LALaslo Alexandru
Laslo Alexandru
LCLaura Chinezu
Laura Chinezu
AIAdrian Ivanescu
Adrian Ivanescu
RCRoxana Octavia Carare
Roxana Octavia Carare
Vascular basement membranes (BMs), composed of laminins, collagen IV, fibronectin, and perlecan, are secreted by endothelial cells, pericytes, smooth muscle cells (SMCs), and astrocytes. In the brain, amyloid beta (Aβ) is eliminated along cerebrovascular BMs of capillaries and arteries as intramural periarterial drainage (IPAD). Ageing modifies vascular BMs, impairing IPAD and leading to Aβ deposition as cerebral amyloid angiopathy. To better understand the molecular determinants of IPAD in ageing, we quantified the relative abundance of BMs secreted by human-derived cerebral endothelial cells, pericytes, brain vascular SMCs, and astrocytes in vitro. We then assessed BM protein levels in SMCs under hypercapnia (8% CO2) as a model of vascular ageing, with and without Aβ exposure. Of the four cell types, we found SMCs secreted the highest levels of fibronectin, laminin, and perlecan, whilst pericytes secreted the highest levels of collagen IV. Hypercapnia increased the expression of collagen IV and fibronectin in SMCs but decreased the expression of laminin. The expression of perlecan increased under hypercapnia, but only in the presence of Aβ. This work highlights the varying compositions of vascular BMs and the dynamic differential responses of SMCs to Aβ and hypercapnia, helping to elucidate the age-related changes that impair IPAD in cerebral vessels.

Verified
Journal Article
Open access
PDF file
SLSavannah Lynn
Savannah Lynn
FSFlavie Soubigou
Flavie Soubigou
JDJennifer Dewing
Jennifer Dewing
ASAmanda Smith
Amanda Smith
JBJoanna Ballingall
Joanna Ballingall
JRJ. Arjuna Ratnayaka
J. Arjuna Ratnayaka
Matrix metalloproteinase-9 (MMP9) and total amyloid-beta (Aβ) are prospective biomarkers of ocular ageing and retinopathy. These were quantified by ELISA in the vitreous and blood from controls (n = 55) and in a subset of age-related macular degeneration (AMD) patients (n = 12) for insights and possible additional links between the ocular and systemic compartments. Vitreous MMP9 levels in control and AMD groups were 932.5 ± 240.9 pg/mL and 813.7 ± 157.6 pg/mL, whilst serum levels were 2228 ± 193 pg/mL and 2386.8 ± 449.4 pg/mL, respectively. Vitreous Aβ in control and AMD groups were 1173.5 ± 117.1 pg/mL and 1275.6 ± 332.9 pg/mL, whilst plasma Aβ were 574.3 ± 104.8 pg/mL and 542.2 ± 139.9 pg/mL, respectively. MMP9 and Aβ showed variable levels across the lifecourse, indicating no correlation to each other or with age nor AMD status, though the smaller AMD cohort was a limiting factor. Aβ and MMP9 levels in the vitreous and blood were unrelated to mean arterial pressure. Smoking, another modifiable risk, showed no association with vitreous Aβ. However, smoking may be linked with vitreous (p = 0.004) and serum (p = 0.005) MMP9 levels in control and AMD groups, though this did not reach our elevated (p = 0.001) significance. A bioinformatics analysis revealed promising MMP9 and APP/Aβ partners for further scrutiny, many of which are already linked with retinopathy.

8 September 2025 in Neuropathology and Applied Neurobiology
Verified
Journal Article
Open access
LALaslo Alexandru
Laslo Alexandru
TBTudor‐Gabriel Boghițoiu
Tudor‐Gabriel Boghițoiu
LCLaura Chinezu
Laura Chinezu
DMDoina Manu
Doina Manu
AIAdrian Dumitru Ivanescu
Adrian Dumitru Ivanescu
RCRoxana‐Octavia Carare
Roxana‐Octavia Carare
Aims: The clusterin ( CLU ) gene is genetically associated with Alzheimer's disease ( AD ), and CLU levels have been shown to positively correlate with regional Aβ deposition in the brain, including in arteries from cerebral amyloid angiopathy (CAA) patients. CLU has also been shown to alter the aggregation, toxicity and blood–brain barrier transport of amyloid beta (Aβ) and has therefore been suggested to play a key role in regulating the balance between Aβ deposition and clearance in both the brain and cerebral blood vessels. However, it remains unclear whether the role of clusterin in relation to Aβ deposition is protective or pathogenic. The aim of this study was to determine how the presence of clusterin influences the pattern of Aβ deposition in hippocampal cerebral vessels. Methods: Intrahippocampal injections of fluorescent human recombinant Aβ alone or in combination with human recombinant CLU were carried out in Clu knockout mice. Aβ deposition and aggregate size in arterioles and capillaries were assessed by confocal microscopy. Results: The presence of CLU significantly reduced the size of Aβ deposits in the walls of cerebral arterioles but not in the tissue outside arterioles. There was no significant difference in overall Aβ deposition within cerebral arterioles and capillaries of mice injected with Aβ + CLU versus Aβ alone. Conclusions: Our findings confirm that CLU directly impacts cerebral vascular Aβ aggregation, the implications of which are particularly relevant to CAA, which is a major cause of cerebral haemorrhage and cognitive decline, particularly in individuals with AD .